Italia markets close in 2 hours 20 minutes

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
23,50-0,04 (-0,17%)
Alla chiusura: 04:00PM EST
23,50 0,00 (0,00%)
Dopo ore: 04:00PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente23,54
Aperto23,31
Denaro23,00 x 1300
Lettera37,36 x 800
Min-Max giorno22,89 - 23,85
Intervallo di 52 settimane17,33 - 59,65
Volume487.557
Media Volume559.970
Capitalizzazione1,341B
Beta (5 anni mensile)1,77
Rapporto PE (ttm)N/D
EPS (ttm)-3,82
Prossima data utili22 feb 2023 - 27 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A52,30
  • GlobeNewswire

    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on January 3, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 30,625 shares of the Company’s common stoc

  • GlobeNewswire

    Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

    Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from monotherapy Phase 2 USC trial announced today Identified Cyclin E driven high-grade serous ovarian cancer patients as initial expansion population for ZN-c3 biomarker monotherapy trial Announced first ZN-c3 clinical development collaboration with Pfizer in BRAF mutant mCRC; Expanded ZN-c3 clinical d

  • GlobeNewswire

    Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

    NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:15 p.m. ET.